By Cort Johnson in Health Rising.
The Best, Most and Least of 2018
A look back at a most interesting year which has to start with Cortene…
It wasn’t supposed to go like this. First, in a disease like ME/CFS, you’re supposed find a repurposed drug or two to treat ME/CFS – then, after years of grinding effort, move onto a brand new drug for the disease. Cortene turned that timetable upside with its introduction of a brand new drug for ME/CFS.
Only time will tell how the CT38 drug trial will turn out, but having a small drug company target a new drug at this disease, successfully and privately raise the money needed to do the trial, get FDA approval for the trial, and actually begin it at the Bateman Horne Center has been sweet to see.
To read the rest of this story, click on the link below: